Is Connect Biopharma Holdings Limited (NASDAQ:CNTB) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Connect Biopharma Holdings Limited at current levels.
A $144M biotech betting the entire IL-4Ra playbook can be rewritten around acute attacks, not chronic maintenance.
Where CNTB is headed
Rademikibart is trying to do something Dupixent never bothered attempting: show up in the emergency room. Sanofi and Regeneron built a $13 billion franchise treating chronic type 2 inflammation with a maintenance biologic. Connect Biopharma is running two Phase 2 trials aimed at the moment the patient is already gasping, the acute exacerbation of asthma and COPD that puts 1.5 million Americans in hospital each year and drives most of the cost in respiratory medicine. If a single subcutaneous dose can measurably shorten or prevent that hospitalization, the drug doesn't compete with Dupixent, it slots into a category that currently has nothing but steroids and oxygen.
Read the full Compass Direction on CNTB
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $2.28).
See the full CNTB analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Connect Biopharma Holdings Limited (NASDAQ:CNTB) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Connect Biopharma Holdings Limited at current levels. A $144M biotech betting the entire IL-4Ra playbook can be rewritten around acute attacks, not chronic maintenance.
What is CNTB's Compass Score?
Connect Biopharma Holdings Limited scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for CNTB?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CNTB page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.